A Direct Method for β-Selective Glycosylation with an N-Acetylglucosamine Donor Armed by a 4-O-TBDMS Protecting Group.

A new direct method for β-selective glycosylation with an N-acetylglucosamine (GlcNAc) donor was developed. This substrate, which can be readily prepared from commercially available GlcNAc in two steps, contains a 4-O-tert-butyldimethylsilyl (TBDMS) protecting group as a key component. We found that this functionality could have a favorable effect on the reactivity of the GlcNAc donor. Glycosylation with the armed donor using primary alcohols in the presence of a catalytic amount of trimethylsilyl trifluoromethanesulfonate (TMSOTf) in 1,2-dichloroethane smoothly gave the desired coupling products in good yields with complete β-selectivity, while sterically hindered acceptors were less efficient.

1. Introduction

N-Acetylglucosamine (GlcNAc) is one of the most abundant naturally occurring monosaccharides, and it exists as a key component of oligosaccharides in glycoproteins and glycolipids that play important biological roles [1]. For example, erythropoietin [2] is an N-linked glycoprotein that enhances hematopoiesis. Several antibiotics, such as TMG-chitotriomycin [3] and bulgecins [4], are also glycosylated with GlcNAc. For the syntheses of glycoconjugates containing GlcNAc residues, it is necessary to use glycosamine (GlcN) donors activated by a phthaloyl [5] and 2,2,2-trichloroethoxycarbonyl [6,7] attached to the amine function. Unfortunately, however, methods using GlcNAc donors suffer from several disadvantages: (1) GlcNAc donors are less reactive than N-modified GlcN donors; (2) harsh conditions (reflux heating [8,9] and microwave irradiation [10,11]) are required to achieve the desired glycosylations; and (3) the corresponding oxazoline byproducts are formed in many cases. In 2008, Christensen and coworkers reported that scandium(III) trifluoromethanesulfonate (Sc(OTf)3) could serve as an effective activator for β-GlcNAc tetraacetate donor 1 and the glycosylation of simple alcohols in refluxing dichloromethane (Figure 1a) gave the desired β-glycosides in high yields [11]. With sterically hindered acceptors, disappointingly, the couplings resulted in low to moderate yields even when using excess amounts of 1 with microwave irradiation at 80 °C. On the other hand, Hashimoto et al. successfully developed glycosylations with a diethyl phosphite donor of GlcNAc 2 in the presence of stoichiometric bis(trifluoromethane)sulfonamide (Tf2NH) at −78 °C (Figure 1b), using sugar secondary alcohols, and then proceeded smoothly to obtain the disaccharides in good yields with complete β-selectivity [12]. However, this glycosylation method requires a stoichiometric amount of Tf2NH and cumbersome preparation of 2. Accordingly, it would be desirable to develop a direct method for β-selective glycosylation with the use of readily available GlcNAc donors under mild conditions without the need for expensive rare-earth metal triflates and excess organic triflates.

Figure 1

Glycosylation with GlcNAc donors: previous work (a,b); this work (c).

Demchenko and coworkers demonstrated that thioglycoside donors of Glc were dramatically activated by the installation of electron-donating benzyl groups to both 4 and 6 positions, and disclosed the correlation between the stability of the glycosyl cations and the reactivity of the glycosyl donors, which led to the development of super-armed donors [13]. Takahashi and Toshima et al. reached a similar conclusion to activate 2,3-dideoxy Glc donors by introducing with a benzyl protecting group at either the 4 or 6 position [14]. This activation, which is called the “remote protecting group effect”, can be explained by considering that the presence of an electron-donating group at either the 4 or 6 position of Glc has a favorable stereoelectronic effect on the ring oxygen and facilitates the formation of an oxocarbenium ion intermediate by the elimination of a leaving group. We thought that the concept of this “remote protecting group effect” could also be valuable in dictating our glycosylation strategy. Based on these considerations, herein we examined a new direct method for β-selective glycosylation under mild conditions with GlcNAc donor 3 armed by a 4-O-tert-butyldimethylsilyl (TBDMS) protecting group (Figure 1c). Herein we describe the successful results of our implementation and the substrate scope of this synthetic sequence.

2. Results and Discussion

Following Ling’s previous report [15], β-GlcNAc tripivaloate 5 was easily prepared in 70% yield by the reaction of free GlcNAc 4 with pivaloyl chloride in pyridine and dichloromethane (Scheme 1). Next, we examined the installation of electron-donating groups at the 4 position of 5. Unfortunately, however, all attempts to introduce a benzyl group using benzyl trichloroacetimidate [16] or 2,4,6-tris(benzyloxy)-1,3,5-triazine (TriBOT) [17] under acid catalysis failed. Not surprisingly, the steric hindrance around the 4-hydroxyl group was quite strong due to the presence of the neighboring bulky pivaloyl groups. To gain a similar “remote protecting group effect”, we examined the utility of TBDMS protection. Thus, the exposure of 5 to silylation with highly reactive tert-butyldimethylsilyl trifluoromethanesulfonate (TBDMSOTf) using 4-dimethylpyridine (DMAP) in pyridine [18] provided the corresponding 4-O-TBDMS-protected GlcNAc 3 in almost quantitative yield. The observed ring vicinal 1H-1H coupling constants (J1,2 = J2,3 = J3,4 = J4,5 = 8–9 Hz) show that the conformation of 3 would still be the 4C1 chair form. For comparison, we also prepared 4-O-acetylated derivative 6.

Scheme 1

Preparation of GlcNAc donors 3 and 6.

To verify the “remote protecting group effect” by the 4-O-TBDMS group, we first examined glycosylation with GlcNAc donors 1, 3, and 6 using 1.5 equivalent of 1-butanol (Scheme 2). All reactions were carried out in 1,2-dichloroethane in the presence of a 20 mol % amount of a variety of acid promoters. When 3 was reacted with trimethylsilyl trifluoromethanesulfonate (TMSOTf) at 25 °C for 48 h, after work-up, the coupling product 7 was obtained in 51% yield with complete β-selectivity, accompanied by the formation of 10% of TBDMS-deprotected 8 along with 26% recovery of the starting material 3 (Entry 1). As expected, at 40 °C, the TMSOTf-catalyzed glycosylation was completed within 12 h to afford 7 and 8 in respective 67% and 12% yields (Entry 2). In contrast, the use of trifluoromethanesulfonic acid (TfOH) resulted in a slight decrease in the product yield, which indicated that TfOH was less efficient, probably due to its strong acidity and/or scarce solubility in this medium. We found that other Lewis acids such as boron trifluoride diethyl etherate (BF3•OEt2) and ytterbium(III) trifluoromethanesulfonate (Yb(OTf)3) were not as effective for our purpose (Entries 4 and 5). In all of these examples, the corresponding oxazoline by-product was detected in a trace amount. Under the conditions of Entry 2, as expected, glycosylation with 4-O-acetylated donor 6 dramatically reduced the coupling yield to 18% (Entry 6). Compared with 6, β-GlcNAc tetraacetate donor 1 also gave only 16% of 10, indicating the size of the acyloxy leaving group had no effect on the reaction efficiency (Entry 7). These experiments suggested that the presence of an electron-donating TBDMS group at the 4 position of GlcNAc was quite effective for promoting the desired β-glycosylation under mild conditions due to its increased reactivity.

Scheme 2

Optimization of reaction conditions during glycosylation with GlcNAc donors 1, 3, 6.

With the optimized conditions in hand, we next investigated the substrate scope in glycosylation with the armed donor 3 as shown in Scheme 3. Glycosylation of 2-(trimethylsilyl)ethanol 11 gave glycoside 17 in 58% yield (Entry 1). Using primary alcohols of 12 and 13, the coupling products 18 and 19 were obtained in 66% and 56% yields, respectively (Entries 2 and 3). Interestingly, the reaction of 3 with thioglycoside Glc acceptor 14 proceeded successfully to give product 20, a convenient building block in oligosaccharide synthesis, in 45% yield without aglycon transfer [19] (Entry 4). Despite several attempts to obtain GlcNAc-β(1→4)-Glc disaccharide 21, a sterically hindered secondary alcohol of Glc 15 was not glycosylated even under high pressure conditions [20] (Entry 6) or with an excess amount of 3 (Entries 5–7). Finally, the coupling with a less reactive primary alcohol 16 of N-Cbz–protected l-serine provided the desired product 22 in only 18% yield (Entry 8).

Scheme 3

Substrate scope in glycosylation with GlcNAc donor 3.

3. Experimental Section

3.1. General Methods

1H- and 13C-NMR spectra were recorded with a JEOL ECA-500 (JEOL Ltd., Tokyo, Japan). High resolution mass spectrometry (HRMS) was performed with a Bruker Daltonics micrOTOF (ESI-TOF, Bruker Corp., Billerica, MA, USA). Specific optical rotation was recorded with a JASCO P-2200 (JASCO Corp., Tokyo, Japan). All reaction solvents were pre-dried with MS4 Å before use. Thin layer chromatography was performed using Merck TLC silica gel 60F254 on glass (Darmstadt, Germany). Developed TLC plates were stained with UV light (254 nm) and p-anisaldehyde solution. High pressure experiments were performed with a LECO PG-200-HPC (LECO Corp., St. Joseph, MI, USA). Purification was carried out by flash column chromatography (Silica Gel 60 N, 40–50 μm, Kanto Chemical Co., Inc., Tokyo, Japan) and gel filtration (Sephadex LH-20, GE Healthcare Bio-Science AB, Uppsala, Sweden). NMR spectra for all new compounds are available in Supplementary Materials.

3.2. General Experimental Procedure and Physical Data for All New Compounds

2-Acetamido-2-deoxy-1,3,6-tri-O-pivaloyl-4-O-tert-butyldimethylsilyl-β- (3). To a solution of 2-acetamido-2-deoxy-1,3,6-di-O-pivaloyl-β-d-glucopyranoside 3 (4.73 g, 10.0 mmol) and 4-dimethylaminopyridine (244 mg, 2.0 mmol) in pyridine (10.0 mL) was added tert-butyldimethylsilyl trifluoromethanesulfonate (2.7 mL, 12.0 mmol) at 4 °C under a nitrogen atmosphere. The reaction was warmed up to 60 °C and stirred at the same temperature for 2 h. After the reaction was complete, the mixture was cool to room temperature and evaporated with toluene (20 mL × 3). The residue was dissolved in ethyl acetate (200 mL) and washed successively with 2.0 M HCl aq. (200 mL), satd. NaHCO3 aq. (200 mL × 2), and brine (200 mL). The aqueous layers were back-extracted with ethyl acetate (200 mL × 2). The combined extracts were dried over Na2SO4, filtered off, and concentrated in vacuo. The crude product was purified by flash column chromatography (ethyl acetate:hexane = 1:4–1:2) to give 2-acetamido-2-deoxy-1,3,6-tri-O-pivaloyl-4-O-tert-butyldimethylsilyl-β-d-glucopyranoside as a colorless syrup (5.62 g, 96%). [α]D +3.17° (c 1.69, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 5.90 (d, 1H, J = 10.3 Hz, NH), 5.55 (d, 1H, J = 8.0 Hz, H-1), 5.08 (t, 1H, J = 8.9 Hz, H-3), 4.47 (dd, 1H, J = 2.6 Hz, J = 11.7 Hz, H-6a), 4.30 (q, 1H, J = 9.6 Hz, H-2), 4.11 (dd, 1H, J = 4.0 Hz, J = 12.0 Hz, H-6b), 3.92 (t, 1H, J = 8.3 Hz, H-4), 3.65 (m, 1H, H-5), 1.86 (s, 3H, Ac), 1.22, 1.21 and 1.17 (s, 27H, 3Piv), 0.85 (s, 9H, tBu), 0.097 and 0.085 (2s, 6H, SiMe2); 13C-NMR (125.8 MHz, CDCl3) δ 179.5, 178.0, 177.0, 169.4, 92.6, 75.2, 68.5, 62.2, 52.5, 39.3, 38.9, 38.7, 27.4, 27.2, 26.7, 25.7, 23.3, 18.0, −4.2, −4.6; HRMS (ESI-TOF) m/z: found [M + Na]+ 610.3381, C29H53NO9Si calcd. for [M + Na]+ 610.3382.

2-Acetamido-4-O-acetyl-2-deoxy-1,3,6-tri-O-pivaloyl-β- (6). To a solution of 2-acetamido-2-deoxy-1,3,6-tri-O-pivaloyl-β-d-glucopyranoside 3 (4.75 g, 10.0 mmol) and 4-dimethylaminopyridine (241 mg, 2.0 mmol) in pyridine (10.0 mL) was added acetic anhydride (1.1 mL, 12.0 mmol) at 4 °C under a nitrogen atmosphere. The reaction was warmed up to room temperature and stirred for 1 h. After evaporation with toluene (20 mL × 3), the residue was dissolved in ethyl acetate (200 mL) and washed successively with 2.0 M HCl aq. (200 mL), satd. NaHCO3 aq. (200 mL × 2), and brine (200 mL). The aqueous layers were back-extracted with ethyl acetate (200 mL × 2). The combined extracts were dried over Na2SO4, filtered off, and concentrated in vacuo. The crude product was purified by flash column chromatography (ethyl acetate:hexane = 1:3 to 2:3) to give 2-acetamido-4-O-acetyl-2-deoxy-1,3,6-tri-O-pivaloyl-β-d-glucopyranoside as a colorless syrup (4.95 g, 96%). [α]D +12.47° (c 3.84, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 6.21 (d, 1H, J = 10.3 Hz, NH), 5.60 (d, 1H, J = 8.6 Hz, H-1), 5.21(m, 2H, J = 9.0 Hz, H-3 and H-4), 4.44 (q, 1H, J = 9.8 Hz, H-2), 4.19 (m, 2H, H-6a and H-6b), 3.87 (m, 1H, H-5), 2.04 (s, 3H, Ac), 1.88(s, 3H, Ac), 1.22, 1.19 and 1.15 (3s, 27H, 3Piv); 13C-NMR (125.8 MHz, CDCl3) δ 179.3, 178.1, 176.9, 169.5, 168.9, 92.5, 72.7, 72.5, 67.9, 61.6, 52.3, 38.9, 38.8, 38.7, 27.0, 26.8, 26.7, 22.9, 20.5; HRMS (ESI-TOF) m/z: found [M + Na]+ 538.2616, C25H41NO10Si calcd. for [M + Na]+ 538.2623.

3.3. General Procedure for the Glycosylation with GlcNAc Donors

To a mixture of GlcNAc donor (1.00 mmol) and acceptor (1.50 mmol) in 1,2-dichloroethane (5.0 mL) was added TMSOTf (36 μL, 0.2 mmol) at 40 °C. After the reaction was stirred at the same temperature for 12 h, it was quenched by the addition of satd. aq. NaHCO3 (50 mL). The resulting mixture was then extracted with CHCl3 (50 mL × 3) and washed with brine (50 mL). The combined extracts were dried over Na2SO4, filtered off, and concentrated in vacuo. The crude product was purified by flash column chromatography to give the desired GlcNAc glycoside. Additional purification using Sephadex LH-20 (MeOH/CHCl3 = 1:1) was performed if needed.

Butyl 2-acetamido-2-deoxy-3,6-di-O-pivaloyl-4-O-tert-butyldimethylsilyl-β- (7). [α]D −12.28° (c 1.49, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 6.09 (d, 1H, J = 9.8 Hz, NH), 5.02 (t, 1H, J = 8.3 Hz, H-3GlcNAc), 4.54 (dd, 1H, J = 3.7 Hz, J = 11.7 Hz, H-6aGlcNAc), 4.41 (d, 1H, J = 6.9 Hz, H-1GlcNAc), 4.10 (m, 2H, H-6bGlcNAc and H-2GlcNAc), 3.85 (t, 1H, J = 7.5 Hz, H-4GlcNAc), 3.80 (m, 1H, OCHb(CH2)2CH3), 3.59 (m, 1H, H-5GlcNAc), 3.40 (m, 1H, OCHa(CH2)2CH3), 1.92 (s, 3H, Ac), 1.44 (m, 2H, OCH2CCH2CH3), 1.25 (m, 2H, O (CH2)2 CCH3), 1.23 and 1.21 (2s, 18H, 2Piv), 0.88 (t, 3H, J = 6.8 Hz, O(CH2)3C), 0.85 (s, 9H, tBu), 0.12 and 0.093 (2s, 6H, SiMe2); 13C-NMR (125.8 MHz, CDCl3) δ 179.1, 178.0, 169.5, 100.7, 74.4, 74.3, 68.8, 68.4, 62.9, 52.5, 39.2, 38.8, 31.4, 27.3, 27.2, 25.7, 23.4, 19.0, 18.0, 13.7, −4.3, −4.7; HRMS (ESI-TOF) m/z: found [M + Na]+ 582.3432, C28H53NO8Si calcd. for [M + Na]+ 582.3433.

Butyl 2-acetamido-2-deoxy-4-hydroxy-3,6-di-O-pivaloyl-β- (8). [α]D −40.52° (c 3.83, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 6.40 (m, 1H, NH), 5.13 (t, 1H, J = 9.7 Hz, H-3GlcNAc), 4.47 (d, 1H, J = 8.6 Hz, H-1GlcNAc), 4.36 (dd, 1H, J = 2.1 Hz, J = 11.7 Hz, H-6aGlcNAc), 4.24 (dd, 1H, J = 5.7 Hz, J = 12.1 Hz, H-6bGlcNAc), 3.86 (q, 1H, J = 9.3 Hz, H-2GlcNAc), 3.75 (m, 1H, OCHb(CH2)2CH3), 3.55 (m, 1H, H-5GlcNAc), 3.47 (m, 1H, OH), 3.44 (m, 1H, H-4GlcNAc), 3.39 (m, 1H, OCHa(CH2)2CH3), 1.84 (s, 3H, Ac), 1.53–1.40 (m, 2H, OCH2CCH2CH3), 1.31–1.21 (m, 2H, O (CH2)2CCH3), 1.15 and 1.13 (2s, 18H, 2Piv), 0.82 (t, 3H, J = 7.5 Hz, O(CH2)3C); 13C-NMR (125.8 MHz, CDCl3) δ 179.8, 179.0, 170.1, 100.8, 75.1, 74.0, 69.6, 69.1, 63.5, 53.9, 38.9, 38.8, 31.3, 27.1, 27.0, 23.0, 18.9, 13.6; HRMS (ESI-TOF) m/z: found [M + Na]+ 468.2567, C28H53NO8Si calcd. for [M + Na]+ 468.2568.

Butyl 2-acetamido-4-O-acetyl-2-deoxy-3,6-di-O-pivaloyl-β- (9). [α]D −8.91° (c 2.875, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 6.03 (m, 1H, NH), 5.22 (t, 1H, J = 10.0 Hz, H-3GlcNAc), 5.11 (t, 1H, J = 9.7 Hz, H-4GlcNAc), 4.57 (d, 1H, J = 8.1 Hz, H-1GlcNAc), 4.20 (dd, 1H, J = 2.3 Hz, J = 12.0 Hz, H-6aGlcNAc), 4.15 (dd, 1H, J = 5.7 Hz, J = 12.1 Hz, H-6bGlcNAc), 4.06 (q, 1H, J = 9.5 Hz, H-2GlcNAc), 3.84 (m, 1H, OCHb(CH2)2CH3), 3.74 (m, 1H, H-5GlcNAc), 3.48 (m, 1H, OCHa(CH2)2CH3), 2.01 and 1.92 (2s, 6H, 2Ac), 1.61–1.49 (m, 2H, OCH2CCH2CH3), 1.34 (m, 2H, O (CH2)2CCH3), 1.22 and 1.15 (2s, 18H, 2Piv), 0.89 (t, 3H, J = 7.3 Hz, O(CH2)3C); 13C-NMR (125.8 MHz, CDCl3) δ 178.6, 178.1, 169.8, 169.0, 100.9, 72.2, 71.8, 69.1, 68.5, 62.3, 53.9, 38.8, 38.7, 31.3, 27.0, 26.8, 23.0, 20.5, 18.9, 13.6; HRMS (ESI-TOF) m/z: found [M + Na]+ 510.2676, C28H53NO8Si calcd. for [M + Na]+ 510.2674.

2-Trimethylsilylethyl 2-acetamido-2-deoxy-3,6-di-O-pivaloy-4-O-tert-butyldimethylsilyl-β- (17). [α]D −16.51°(c 3.465, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 6.26 (d, 1H, J = 9.8 Hz, NHGlcNAc), 5.04 (t, 1H, J = 8.6 Hz, H-3GlcNAc), 4.49 (dd, 1H, J = 1.95 Hz, J = 11.5 Hz, H-6aGlcNAc), 4.36 (d, 1H, J = 6.9 Hz, H-1GlcNAc), 4.05 (m, 2H, H-2GlcNAc, H-6bGlcNAc), 3.85 (m, 1H, OCHbCH2SiMe3), 3.81 (t, 1H, J = 8.0 Hz, H-4GlcNAc), 3.51 (m, 1H, H-5GlcNAc), 3.45 (m, 1H, OCHaCH2SiMe3), 1.88 (s, 3H, Ac), 1.19 and 1.17 (2s, 18H, 2Piv), 0.83 (m, 2H, OCH2CSiMe3), 0.82 (s, 9H, tBu), 0.075 and 0.044 (2s, 6H, SiMe2), −0.055 (s, 9H, SiMe3); 13C-NMR (125.8 MHz, CDCl3) δ 179.4, 178.0, 169.5, 100.2, 74.2, 68.8, 66.4, 62.8, 53.0, 39.2, 38.8, 27.3, 27.2, 25.7, 23.5, 18.0, 17.8, −1.5, −4.2, −4.6; HRMS (ESI-TOF) m/z: found [M + Na]+ 626.3525, C29H57NO8Si2 calcd. for [M + Na]+ 626.3515.

2-Acetamido-2-deoxy-3,6-di-O-pivaloyl-4-O-tert-butyldimethylsilyl-β- (18). [α]D +0.22° (c 1.04, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 5.63 (d, 1H, J = 9.8 Hz, NHGlcNAc), 5.50 (d, 1H, J = 5.2 Hz, H-1Gal), 4.99 (t, 1H, J = 8.9 Hz, H-3GlcNAc), 4.56 (dd, 1H, J = 2 Hz, J = 8 Hz, H-3Gal), 4.54 (d, 1H, J = 3 Hz, H-1GlcNAc), 4.52 (dd, 1H, J = 3.3 Hz, J = 4.3 Hz, H-6aGlcNAc), 4.29 (m, 1H, H-2Gal), 4.11 (m, 3H, H-6bGlcNAc, H-4Gal and H-2GlcNAc), 3.92 (m, 2H, H-5Gal and H-6aGal), 3.84 (t, 1H, J = 8 Hz, H-4GlcNAc), 3.67 (dd, 1H, J = 8.85 Hz, J = 12.9 Hz, H-6bGal), 3.55 (m, 1H, H-5GlcNAc), 1.94 (s, 3H, Ac), 1.49 (s, 3H, COOMe2a), 1.42 (s, 3H, COOMe2a), 1.31 (s, 3H, COOMe2b), 1.30 (s, 3H, COOMe2b), 1.23 and 1.20 (2s, 18H, 2Piv), 0.844 (s, 9H, tBu), 0.093 and 0.064 (2s, 6H, SiMe2); 13C-NMR (125.8 MHz, CDCl3) δ 179.1, 178.0, 170.0, 109.2, 108.5, 101.8, 96.2, 75.1, 74.5, 71.1, 70.6, 70.2, 68.9, 68.2, 68.1, 62.7, 53.2, 39.2, 38.8, 27.4, 27.2, 26.1, 25.9, 25.7, 24.9, 23.5, 18.0, −4.2, −4.6; HRMS (ESI-TOF) m/z: found [M + Na]+ 768.3954, C36H63NO13Si calcd. for [M + Na]+ 768.3961.

Methyl (2-acetamido-2-deoxy-3,6-di-O-pivaloyl-4-O-tert-butyldimethylsilyl-β- (19). [α]D +1.70° (c 1.49, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.30 (m, 15H, 3Ph), 5.70 (d, 1H, J = 9.2 Hz, NHGlcNAc), 4.98 and 4.80 (2d, 2H, J = 11 Hz, OCH2Ph), 4.96 (t, 1H, J = 7.8 Hz, H-3GlcNAc), 4.84 and 4.56 (2d, 2H, J = 11 Hz, OCH2Ph), 4.77 and 4.66 (2d, 2H, J = 12 Hz, OCH2Ph), 4.53 (d, 1H, J = 7.0 Hz, H-1Glc), 4.49 (dd, 1H, J = 3.8 Hz, J = 11.9 Hz, H-6aGlcNAc), 4.39 (d, 1H, J = 6.9 Hz, H-1GlcNAc), 4.11 (dd, 1H, J = 7.5 Hz, J = 11.8 Hz, H-6bGlcNAc), 4.08 (q, 1H, J = 9.0 Hz, H-2GlcNAc), 4.02 (dd, 1H, J = 1.5 Hz, J = 10.5 Hz, H-2Glc), 3.97 (t, 1H, J = 9.5 Hz, H-3Glc), 3.82 (t, 1H, J = 7.4 Hz, H-4GlcNAc), 3.72 (dd, 1H, J = 2.3 Hz, J = 9.3 Hz, H-5Glc), 3.60 (m, 2H, H-6aGlc and H-5GlcNAc), 3.48 (dd, 1H, J = 3.8 Hz, J = 10.3 Hz, H-6bGlc), 3.46 (t, 1H, J = 10 Hz, H-4Glc), 3.35 (s, 3H, OMe), 1.83 (s, 3H, Ac), 1.19 and 1.16 (2s, 18H, 2Piv), 0.86 (s, 9H, tBu), 0.097 and 0.074 (2s, 6H, SiMe2); 13C-NMR (125.8 MHz, CDCl3) δ178.8, 177.9, 169.3, 138.8 ,138.2, 138.1, 128.43, 128.39, 128.3, 128.1, 127.8, 127.77, 127.5, 100.9, 97.8, 82.0, 79.6, 77.4, 75.6, 74.7, 74.5, 73.9, 73.2, 69.5, 68.3, 67.3, 63.0, 55.0, 52.5, 39.1, 38.8, 27.2, 27.1, 25.7, 23.4, 17.9, −4.3, −4.7; HRMS (ESI-TOF) m/z: found [M + Na]+ 972.4902, C52H75NO13Si calcd. for [M + Na]+ 972.4900.

Phenyl (2-acetamido-2-deoxy-3,6-di-O-pivaloyl-4-O-tert-butyldimethylsilyl-β-d-glucopyranosyl)-(1→6)-2,3,4-tri-O-benzoyl-1-thio-β-d-glucopyranoside (20). [α]D −0.14° (c 2.06, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.96–7.23 (20H, 4Ph), 5.86 (t, 1H, J = 9.5 Hz, H-3Glc), 5.62 (d, 1H, J = 9.8 Hz, NHGlcNAc), 5.44 (t, 1H, J = 9.7 Hz, H-4Glc), 5.39 (t, 1H, J = 9.7 Hz, H-2Glc), 5.00 (m, 2H, H-3GlcNAc and H-1Glc), 4.51 (dd, 1H, J = 2.6 Hz, J = 11.7 Hz, H-6aGlcNAc), 4.36 (d, 1H, J = 8.0 Hz, H-1GlcNAc), 4.11–4.02 (m, 3H, H-2GlcNAc, H-6aGlc and H-6bGlcNAc), 3.97 (m, 1H, H-5Glc), 3.82 (t, 1H, J = 8.6 Hz, H-4GlcNAc), 3.62 (dd, 1H, J = 6.3 Hz, J = 12.0 Hz, H-6bGlc), 3.46 (m, 1H, H-5GlcNAc), 1.86 (s, 3H, Ac), 1.23 and 1.20 (2s, 18H, 2Piv), 0.85 (s, 9H, tBu), 0.093 and 0.070 (2s, 6H, SiMe2); 13C-NMR (125.8 MHz, CDCl3) δ 178.7, 178.0, 170.0, 165.6, 165.4, 164.9, 133.6, 133.4, 133.3, 133.2, 131.5, 129.9, 129.8, 129.6, 129.3, 129.1, 128.7, 128.5, 128.3, 128.2, 101.8, 86.2, 78.1, 74.9, 74.6, 74.2, 70.3, 68.9, 68.9, 67.6, 62.5, 53.5, 39.2, 38.8, 27.4, 27.2, 25.7, 23.3, 18.0, −4.1, −4.6; HRMS (ESI-TOF) m/z: found [M + Na]+ 1092.4225, C52H75NO13Si calcd. for [M + Na]+ 1092.4206.

Methyl (2-acetamido-2-deoxy-3,6-di-O-pivaloyl-4-O-tert-butyldimethylsilyl-β- (21). [α]D −4.12°(c 0.98, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.53–7.24 (m, 15H, 3Ph), 4.96 and 4.72 (2d, 2H, J = 11.5 Hz, OCH2Ph), 4.86 and 4.30 (2d, 2H, J = 12.3 Hz, OCH2Ph), 4.67 and 4.54 (2d, 2H, J = 12.3 Hz, OCHPh), 4.66 (t, 1H, J = 9.5 Hz, H-3GlcNAc), 4.54 (d, 1H, J = 3.4 Hz, H-1Glc), 4.46 (d, 1H, J = 10.3 Hz, NHGlcNAc), 4.40 (dd, 1H, J = 2.0 Hz, J = 11.7 Hz, H-6aGlcNAc), 4.05 (d, 1H, J = 8.6 Hz, H-1GlcNAc), 3.87 (q, 1H, J = 9.4 Hz, H-2GlcNAc), 3.81 (t, 1H, J = 9.2 Hz, H-6aGlcNAc), 3.75 (t, 1H, J = 9.5 Hz, H-6bGlcNAc), 3.65 (dd, 1H, J = 6.9 Hz, J = 11.5 Hz, H-4Glc), 3.60 (m, 1H, H-5GlcNAc), 3.59 (dd, 1H, J = 3.6 Hz, J = 10.5 Hz, H-6aGlc), 3.55 (t, 1H, J = 8.9 Hz, H-4GlcNAc), 3.44 (dd, 1H, J = 1.3 Hz, J = 10.4 Hz, H-6bGlc), 3.39–3.33 (m, 5H, H-3Glc, H-2Glc, OMe), 3.29 (m, 1H, H-5Glc), 1.68 (s, 3H, Ac), 1.17 (2s, 18H, 2Piv), 0.87 (s, 9H, tBu), 0.053 and 0.019 (2s, 6H, SiMe2); 13C-NMR (125.8 MHz, CDCl3) δ 178.7, 178.0, 169.2, 139.7, 138.3, 137.5, 129.4, 129.2, 129.1, 129.0, 128.3, 128.1, 128.0, 127.9, 127.8, 127.7, 127.5, 127.0, 100.7, 98.6, 79.6, 78.2, 75.9, 75.0, 73.9, 73.8, 73.4, 69.6, 69.4, 67.1, 63.3, 55.3, 54.3, 39.1, 38.8, 27.4, 27.2, 27.0, 25.7, 23.4, 18.0, −4.1, −4.4; HRMS (ESI-TOF) m/z: found [M + Na]+ 972.4917, C52H75NO13Si calcd. for [M + Na]+ 972.4900.

N-(Benzyloxycarbonyl) 3-O-(2-acetamido-2-deoxy-3,6-di-O-pivaloyl-4-O-tert-butyldimethylsilyl-β- (22). [α]D −4.89° (c 2.13, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.34 (m, 5H, Ph), 5.94 (m, 1H, NHGlcNAc), 5.78 (d, 1H, J = 8.6 Hz, NHSer), 5.13 and 5.09 (2d, 2H, J = 12.3 Hz, CH2Ph), 5.00 (t, 1H, J = 8.9 Hz, H-3GlcNAc), 4.48 (m, 2H, H-6aGlcNAc and H-2Ser), 4.39 (d, 1H, J = 7.4 Hz, H-1GlcNAc), 4.16 (dd, 1H, J = 3.8 Hz, J = 10.8 Hz, H-3aSer), 4.07 (dd, 1H, J = 4.5 Hz, J = 11.5 Hz, H-6bGlcNAc), 4.02 (q, 1H, J = 8.8 Hz, H-2GlcNAc), 3.83 (t, 1H, J = 8.3 Hz, H-4GlcNAc), 3.78 (dd, 1H, J = 3.5 Hz, J = 10.5 Hz, H-3bSer), 3.73 (s, 3H, OMe), 3.50 (m, 1H, H-5GlcNAc), 1.84 (s, 3H, Ac), 1.22 and 1.18 (s, 18H, 2Piv), 0.84 (s, 9H, tBu), 0.092 and 0.061 (2s, 6H, SiMe2); 13C-NMR (125.8 MHz, CDCl3) δ 179.2, 177.9, 170.2, 170.1, 156.0, 136.2, 128.4, 128.1, 101.0, 74.5, 74,49, 68.4, 68.0, 67.0, 62.3, 53.9, 53.0, 52.6, 39.2, 38.8, 27.3, 27.2, 23,3, 18.0, −4.3, −4.7; HRMS (ESI-TOF) m/z: found [M + Na]+ 761.3651, C36H58N2O12Si calcd. for [M + Na]+ 761.3651.

4. Conclusions

In summary, based on the concept of the “remote protecting group effect”, we developed a direct method for β-selective glycosylation under mild conditions with GlcNAc donor 3 bearing a TBDMS protecting group at the 4 position. Thus, the attachment of this functionality could improve the reactivity of 3 compared with that of β-GlcNAc tetraacetate 1. Furthermore, the substrate scope in this glycosylation revealed that, while primary alcohols gave the corresponding coupling products in good yields, sterically hindered alcohols were less efficient. Further studies to improve this glycosylation using GlcNAc donors are currently in progress in our laboratories.